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1. Introduction 
It is well established that the aging process is associated with numerous changes in the 
human body. One of the most significant age-related anatomical changes is that which 
happens to the skeletal muscle mass. Aging process is associated with loss of muscle mass 
and strength. The term “sarcopenia” is used to indicate progressive reduction in muscle 
mass, muscle strength and function that affects older people. Sarcopenia is derived from the 
Greek word “sarx” for flesh and “penia” for loss (M.S. John Pathy 2006). This term was first 
used by Rosenberg in 1988 at a symposium on nutritional status and body composition to 
bring awareness and draw attention to this significant but then understudied problem of 
aging (M.S. John Pathy 2006). Sarcopenia is now acknowledged as an important geriatric 
syndrome and is considered one of the hallmarks of aging process (Cruz-Jentoft, et al. 
2010b). Research on the process, causes, consequences, management and treatment of age-
related muscle loss (mass, strength and quality) have exploded since the 1990’s (Janssen 
2010; Schranger M 2003). 
Sarcopenia results in unfavourable and detrimental effects on an older person’s physical 
function. Muscle mass decrease is probably the single most frequent cause of late-life 
disability among older people. It is directly responsible for functional impairment with loss 
of strength, and increased likelihood of falls and fractures (Y Rolland 2008). As muscles 
account for 60% of the body protein stores, the reduction in lean body mass has other health 
effects independent of its functional consequences (Y Rolland 2008). A number of 
physiological functions that take place within the muscle tissues have an essential role in 
human metabolism. For example, muscles are important body protein reserves and energy 
that can be used in extreme conditions such as stress or malnutrition; amino-acids can be 
mobilised during acute infections and are also used as building blocks for antibodies while 
hormones are produced and catabolised within the muscle tissue (M.S. John Pathy 2006). In 
other words, reduction in muscle mass has an adverse impact on metabolic adaptation and 
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immunological response to disease. Nevertheless, there remains considerable unexplained 
variation in muscle mass and strength among older people which may partly be explained 
by the observation that muscle mass and strength in later life reflect not only the rate of loss 
but also the peak attained earlier in life (A A Sayer 2008; M.S. John Pathy 2006). Thus, a life 
course model of sarcopenia will enable us to understand sarcopenia, its influences and 
develop effective interventions (A A Sayer 2008). This is shown in Figure 1. 
Age  
Fig. 1. A life course model of sarcopenia. 
Taking all these into account, sarcopenia is now one of the main focal points in aging 
research; drawing attention to its epidemiology, causes, consequences as well as health care 
costs. Increasing awareness of sarcopenia and promoting health enhancing strategies to 
overcome sarcopenia offers numerous benefits. This chapter provides an overview of the 
current literature on sarcopenia in older people. 
2. Definition of sarcopenia 
Sarcopenia is now defined as a geriatric syndrome characterised by progressive and 
generalised loss of skeletal muscle mass, strength and quality associated with ageing (Cruz-
Jentoft, et al. 2010b). Sarcopenia is also associated with multiple contributing risk factors 
through a common and complex path, with a risk of adverse outcomes such as increased 
frailty and physical and mobility disability leading to loss of dependence, poor quality of 
life, increased healthcare costs and ultimately death (Cruz-Jentoft, et al. 2010b; M.S. John 
Pathy 2006; Y Rolland 2008 ). 
Despite agreement in the conceptual definition of sarcopenia, the consensus on the 
operational definition of sarcopenia has yet to be reached. The definition of sarcopenia has 
been thoroughly discussed and the pooled consensus is that sarcopenia is mainly, but not 
only an age-related condition defined by the combined presence of reduced muscle mass 
and muscle function (Cruz-Jentoft, et al. 2010a; Muscaritoli, et al. 2010).  
The European Working Group on Sarcopenia in Older People (EWGSOP) developed a 
practical clinical definition and consensus diagnostic criteria for age-related sarcopenia 
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(Cruz-Jentoft, et al. 2010a). The EWGSOP included representatives from four participant 
organisations i.e. the European Union Geriatric Medicine Society (EUGMS), the European 
Society for Clinical Nutrition and Metabolism (ESPEN), the International Associations of 
Gerontology and Geriatrics -European Region (IAGG-ER) and the International Association 
of Nutrition and Aging (Valderrama-Gama, et al.). The EWGSOP recommends using the 
presence of both low muscle mass and low muscle function (strength or performance) for 
the diagnosis of sarcopenia (Cruz-Jentoft, et al. 2010a). The diagnosis requires the presence 
of criterion 1 and the presence of either criterion 2 or 3 (see Table 1). 
 
Diagnosis is based on documentation of criterion 1 plus (criterion 2 or criterion 3) 
  
1. Low muscle mass 
2. Low muscle strength 
3. Low physical performance 
Source: Report of the EWGSOP. Sarcopenia: European consensus on definition and diagnosis. Age and 
Ageing, 2010: 39: 412-423. 
Table 1. Criteria for the diagnosis of sarcopenia 
The EWGSOP report argues that the rationale in using two criteria is that muscle strength 
does not depend solely on muscle mass and the relationship between strength and mass is 
not linear (Cruz-Jentoft, et al. 2010a). Furthermore, defining sarcopenia in terms of muscle 
mass alone is too narrow and may be of limited clinical value. The EWGSOP report also 
categorised sarcopenia into three staging that reflects the severity of the condition: - a 
presarcopenia stage (characterised by low muscle mass without impact on muscle strength 
or physical performance), sarcopenia stage (characterised by low muscle mass and low 
muscle strength or low physical performance) and severe sarcopenia (characterised by low 
muscle mass, low muscle strength and low physical performance) (Cruz-Jentoft, et al. 
2010a).  
2.1 Measuring sarcopenia – The quantitative approach 
The measurement variables include muscle mass, strength and physical performance. Age-
related decline in muscle mass has been documented by lean body mass measurements with 
dual X-ray absorptiometry (DXA), muscle cross sectional areas quantified by bioimaging 
methods such as X-ray computed tomography (CT) and magnetic resonance imaging (MRI), 
estimation of the volume of fat and lean body mass using bioimpedance analysis (BIA) and 
finally anthropometric measurements (i.e. calculations based on mid-upper arm 
circumference and skin-fold thickness) (M.S. John Pathy 2006). DXA is a better method for 
measuring muscle mass than bioelectric impedance and anthropometric measurements. 
DXA has the advantage of providing precise estimates of skeletal lean mass and being non-
invasive compared to other accurate laboratory-based methods such as neutron activation 
and 40K counting (M.S. John Pathy 2006). However, DXA is not portable and cannot be used 
in large-scale epidemiological studies. BIA may be considered as a portable alternative to 
DXA (Cruz-Jentoft, et al. 2010a). Muscle strength can be measured using isometric hand 
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grip. Muscle strength alone has been shown to be the most useful indicator of age-related 
changes in muscle for use in clinical practice (Hairi NN 2010). Grip strength is a good simple 
measure of muscle strength and correlates with leg strength (Cruz-Jentoft, et al. 2010a). 
Other measures of muscle strength include knee flexion /extension and peak expiratory 
flow (PEF) (Cruz-Jentoft, et al. 2010a). With regards to physical performance, a wide range 
of tests are available including Tinetti Performance Oriented Mobility Test, Gait Speed, 
Functional Independence Measure and the Timed Get-Up-and-Go (TGUG) test (Guralnik 
and Luigi 2003). Cut-off points depend upon the measurement technique chosen and on the 
availability of reference studies. The EWGSOP recommends the use of normative (healthy 
young adult) rather than other predictive reference populations (Cruz-Jentoft, et al. 2010a). 
To date, sarcopenia has not been included in common classifications of disease (i.e. 
International Classification of Diseases), although some recent initiatives are trying to move 
in this direction. 
3. Aetiology and pathogenesis of sarcopenia 
The aetiology of sarcopenia is multifactorial (Cruz-Jentoft, et al. 2010b; Lang, et al. 2010; Y 
Rolland 2008 ). Multiple risk factors contribute to the development and progression of 
sarcopenia. These risk factors can be grouped into several categories such as constitutional 
factors, the aging process, certain life habits such as decreased protein intake, disuse or poor 
physical activity including lack of exercise, the use of tobacco and alcohol intake, changes in 
living conditions such as prolonged bed rest and immobility and chronic health conditions 
(Cruz-Jentoft, et al. 2010b). Table 2 shows the risk factors of sarcopenia. 
The pathogenesis of sarcopenia is part of a complex process of age-related changes in 
musculoskeletal cellular as well as tissue structure and function (Doherty 2003; Lang, et al. 
2010). Social and lifestyle behaviours such as physical inactivity, smoking, poor diet, being 
obese, as well as age-related hormonal, neurological, immunological and metabolic factors 
are important risk factors (M.S. John Pathy 2006). Genetic susceptibility also plays a role in 
sarcopenia formation(Muscaritoli, et al. 2010). The putative causes of sarcopenia have been 
catergorised into “intrinsic” and “extrinsic” factors (M.S. John Pathy 2006; Muscaritoli, et al. 
2010). Reductions in anabolic hormones (testosterone, estrogens, growth hormones, insulin 
like growth factor-1), increases of apoptotic activities in the myofibers, increases of 
proinflammatory cytokines (e.g. TNF-α, IL-6), oxidative stress due to accumulation of free 
radicals, changes of the mitochondrial function of muscle cells and a decline in the number 
of α-motoneurons are some of the intrinsic factors involved (Lang, et al. 2010; Muscaritoli, et 
al. 2010). Deficient intake of energy and protein, reduced intake of vitamin D, acute and 
chronic co-morbidities and reduced physical activity are some of the extrinsic conditions 
leading to sarcopenia (Cruz-Jentoft, et al. 2010b; Muscaritoli, et al. 2010). Figure 2 shows the 
factors contributing to sarcopenia and its consequences. 
What is not known is which factors or pathways are relatively more or less important with 
regards to the severity and rate of development of sarcopenia components; muscle mass, 
strength and quality. Each factor potentially contributes differently to the loss of muscle 
mass, strength and quality and it is likely that there is considerable individual variability in 
the interactions of these factors (M.S. John Pathy 2006).  
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FACTORS AGING PROCESS 
CHRONIC HEALTH 
CONDITIONS 
   
Constitutional 
Female 
Low birth weight 
Genetic susceptibility 
Increase muscle turnover 
ŃCatabolic stimuli 
Ń Protein degradation 
Low grade inflammation 
ŅAnabolic stimuli 
ŅProtein synthesis 
 
Cognitive impairment 
Mood disturbances 
Diabetes Mellitus 
Heart Failure 
Liver Failure 
Renal Failure 
Respiratory Failure 
Osteoarthritis 
Chronic Pain 
Lifestyle 
Malnutrition 
Low protein intake 
Alcohol abuse 
Smoking 
Physical inactivity 
Reduced number of muscle cells 
ŃMyostatin (Ņ recruitment) 
Ń Apoptosis 
 
Obesity 
Catabolic effects of drugs 
Living conditions 
Starvation 
Bed rest 
Immobility deconditioning 
Weightlessness 
Hormonal deregulation 
Ņ Testosterone, DHEA 
production 
ŅOestrogen production 
Ņ 1-25 (OH)2 vitamin D 
Ń Thyroid Function 
Ņ Growth hormone, IGF-1 
Ń Insulin resistance 
 
 
 
Changes in neuromuscular system
Ņ CNS input (loss of α- motor    
neurons) 
Neuromuscular  disjunction 
Ņ Cilliary neurotrophic factor 
Ņ Motor unit firing rate 
 
 
Cancer ? 
Chronic inflammatory Disease? 
 
Mitochondrial dysfunction 
Ņ Peripheral vascular flow  
Source: Cruz-Jentoft AJ, Landi F, Topinkova E et al. Understanding sarcopenia as a geriatric syndrome. 
Current Opinion in Clinical Nutrition and Metabolic Care. 2010; 13: 1-7 
Table 2. Risk factors of sarcopenia 
4. Functional consequences of sarcopenia 
Age-related loss of muscle mass and strength result in decreased functional limitation and 
physical disability among older people. Using the Nagi Model of Disablement pathology 
(e.g. sarcopenia) first leads to impairment such as lower extremity weakness (Steven M 
Albert and Vicki A Freedman 2010). When this crosses some threshold, functional 
impairment begins to show (which is measurable via gait speed below age-sex appropriate 
norm) and this in turn will lead to physical disability, e.g. needing help to cross the street 
(Steven M Albert and Vicki A Freedman 2010). This is as shown in Figure 3.  
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Sources: M Muscaritoli, S.D Anker, J. Argiles et al. Consensus definition of sarcopenia, cachexia and pre-
chaexia: Joint document elaborated by Special Interest Groups (SIG) “cachexia-anorexia in chronic 
wasting diseases” and “nutrition in geriatrics”. Clinical Nutrition;  2010 (29): 154 – 159 and  Doherty T. 
Aging and Sarcopenia. J. Appl Physiol. 2003 (95): 1717-1727 and Cruz-Jentoft AJ, Landi F, Topinkova E 
et al. Understanding sarcopenia as a geriatric syndrome. Current Opinion in Clinical Nutrition and 
Metabolic Care. 2010; 13: 1-7 
Fig. 2. Factors contributing to sarcopenia and its consequences 
 
Fig. 3. Sarcopenia leading to disability following the Nagi Model of Disablement 
Recent cross sectional and longitudinal studies have shown that loss of muscle mass and/or 
strength increase the risk of poor physical function among older people (A B. Newman, et al. 
2003; I Janssen 2006; MJ. Delmonico, et al. 2007). However, due to the various operational 
definitions used, the relationship between age-related muscle mass and poor physical function 
has not been consistent. A recent study by Hairi et al. showed that in older men, low muscle 
strength, low muscle mass and low muscle quality (specific forces) are associated with 
physical disability in basic Activities of Daily Living (ADLs)(Hairi NN 2010) (Table 3).  
www.intechopen.com
 
Sarcopenia in Older People 
 
35 
 
Crude Age adjusted 
Multivariable 
adjusted* 
Prevalence Ratio (95 % CI) 
Physical disability (ADL) 
    
Grip strength§ 2.83  (1.91,  4.20) 1.79  (1.17,  2.74) 1.09  (0.72,  1.65) 
Quadriceps strength§ 4.48  (2.43,  8.27) 3.24  (1.68,  6.23) 2.07 (1.14,  3.78) 
    
aLM/height + 1.89  (1.25,  2.86) 1.29  (0.84,  1.99) 1.41  (0.88,  2.26) 
aLM/fat mass≠ 2.99  (2.05,  4.38) 2.79  (1.93,  4.05) 2.08  (1.37,  3.15) 
residuals 2.95  (2.00,  4.36) 2.18  (1.43,  3.32) 1.75  (1.10,  2.78) 
    
Upper extremity 
specific force §, ¶ 
1.95  (1.26,  3.03) 1.63  (1.07,  2.49) 1.19  (0.77,  1.85) 
Lower extremity 
specific force §, # 
3.38  (1.82,  6.30) 2.71  (1.44,  5.08) 2.01  (1.05,  3.83) 
*Adjusted for country of birth, age group, education level, PASE score, co-morbidity, stroke, arthritis, 
depressive symptoms.  
+Additionally adjusted for obesity.  
≠Additionally adjusted for height. 
§ Additionally adjusted for pain. 
ǁ Ratio of grip strength (measured in kg of force) to arm lean mass  
# Ratio of quadriceps strength (measured in kg of force) to leg lean mass. 
Source: Hairi NN, Cumming R, Naganathan V et al. Loss of Muscle Strength, Mass (Sarcopenia), and 
Quality (Specific Force) and Its Relationship with Functional Limitation and Physical Disability: The 
Concord Health and Ageing in Men Project. Journal of the American Geriatrics Society. 2010: 58: 2055-2062 
Table 3. Prevalence ratios for low muscle strength, muscle mass and muscle quality and 
physical disability, CHAMP Study.  
The relationship between age-related muscle changes and poor physical function is 
complex. Muhlberg and Siber described three possible “vicious loops” that involve feedback 
from physiological and behavioural systems. The “vicious loops” are the immobilization 
loop, the nutritional loop and the metabolic loop (M.S. John Pathy 2006). The vicious loop 
between sarcopenia and immobilization is described as: sarcopenia ń neuromuscular 
impairment ń falls and fractures ń immobilization ń sarcopenia. The second loop is the 
“nutritional” vicious loop between sarcopenia and malnutrition: sarcopenia   ń 
immobilization ń decline of nutrition skills (empty refrigerator) ń malnutrition impaired 
protein synthesis ń sarcopenia. Finally,  the “metabolic” vicious loop between sarcopenia 
and the decline of protein reserve in the body: sarcopenia ń decline of protein reserve of the 
body ń diminished capacity to meet the extra demand of protein synthesis associated 
disease and injury ń sarcopenia. 
5. Prevention and treatments for sarcopenia 
As sarcopenia (loss of muscle strength, muscle mass and quality) was found to be associated 
with poor physical function, improvements in muscle strength would prevent 
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immobilization and break the cycle. Physical activity, especially resistance exercise 
attenuates and may reverse age associated decreases in muscle strength as well as improve 
physical agility. Other interventions such as combinations of exercise with dietary 
supplements, hormone replacement, anti-inflammatory and other pharmacological 
treatments are still being investigated. 
5.1 The role of exercise and increased physical activity 
Exercise stimulates the release of growth hormones that promotes healthy muscle mass 
(M.S. John Pathy 2006). Although any exercise is better than no exercise at all, in terms of 
preventing loss of lean muscle mass, resistance exercise is preferred (Y Rolland 2008 ). 
Resistance exercise increases muscle protein synthesis rate over proteolysis and results in a 
net increase in contractile protein mass and hypertrophy of muscle fibres. Strength training 
being part of resistance exercise remains highly effective in maintaining muscular strength 
throughout life (Mühlberg and Sieber 2004). However, in older people, strength levels fall 
far more rapidly, independent of training (Y Rolland 2008 ). This is due to the changes in 
hormones such as testosterone and growth hormones which decline more rapidly and 
dramatically after the age of 60 years. Reduction in the circulation of these hormones will 
result in a shift in the balance between muscle protein synthesis and protein breakdown 
(Borst 2004). The vast majority of the literature on prevention and treatment of sarcopenia is 
related to the effects of exercise. These studies have demonstrated that progressive 
resistance training in older people results in substantial improvements in muscle strength 
and mass (Borst 2004). The improvements in muscle strength are smaller in absolute terms 
but similar in relative terms, compared to the younger population. What remains unclear 
are issues such as optimal duration, frequency and type of resistive exercise, combinations 
of resistive and aerobic training, compliance and long term maintenance, adjuvant 
nutritional supplementation and/or pharmacologic treatment. A recent review by Borst SE 
suggested that resistance training is an effective intervention for increasing muscle mass 
and strength in older people (Borst 2004). 
Additional benefits of resistance exercise include normalisation of blood pressure, improved 
insulin sensitivity, decreased total and abdominal fat, increased metabolic rate, prevention 
of bone loss, reduction of risk for falls, reduced pain and improved physical function. Other 
forms of exercise, such as aerobic exercises have well-established benefits on cardiovascular 
fitness, improving lipid profile and flexibility (M.S. John Pathy 2006). Therefore, engaging in 
some form of resistance training is essential to preserve and increase muscle mass and 
strength.  
5.2 Nutritional strategies for prevention and treatment of sarcopenia 
Aging is associated with a progressive reduction in food intake, which predisposes to 
energy-protein malnutrition. In other words, aging is associated with physiological 
anorexia, decrease in caloric intake and weight loss (Marcell 2003). The decline in food 
intake that happens even in healthy older people has been termed “anorexia of ageing” 
(M.S. John Pathy 2006). Studies have shown that low dietary energy intake is common 
among healthy older people. Other factors that influence food intake in older people include 
psychological state (e.g. depression or depressive symptoms), social support and network 
(e.g. loneliness) and physical change (poor dentition, impaired taste and smell). Changes in 
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food preferences with an increased liking for sweet and protein-poor foods have also been 
reported among older people. Dietary factors that contribute to sarcopenia include inadequate 
protein intake, insufficient calorie intake and low level metabolic acidosis (Paddon-Jones, et al. 
2008). Metabolic efficiency in older people has been shown to be lower. Older people have a 
higher rate of protein catabolism and needing a higher requirement for dietary protein than 
their younger counterparts (Paddon-Jones, et al. 2008). There are research findings to support 
the ability of dietary protein to stimulate protein synthesis in older people. A review paper by 
Borst concludes that there is insufficient research to define an optimal value for protein 
ingestion (moderate intake or high intake)(Borst 2004). There are also uncertainties linking 
high protein intake to increased risk of impaired kidney function in healthy older people. This 
is further complicated by the fact that renal function decreases with age.  
Older people have reduced food intake and increased protein requirements. Therefore, 
older people should strive to ensure adequate intake of protein (leucine-enriched amino 
acids and possibly creatine) from a variety of sources, accompanied by an increase in fruits 
and vegetables.  
5.3 Hormone replacement and management of sarcopenia 
Aging is accompanied by declining levels of many essentials hormones in the body, 
especially growth hormone (GH) and testosterone. The Reproductive-Cell Cycle Theory of 
Aging is a new theory explaining the process of aging (Bowen and Atwood 2004). This 
theory proposes that the rate of aging is synonymous with the rate of change. The rate of 
change/aging is most rapidly seen during the fetal period. Reproductive hormones are 
known to regulate mitogenesis (process by which a cell divides to form two daughter cells), 
and differentiation (process by which a cell becomes specialised to perform unique 
functions), hence aging is primarily regulated by these hormones (Bowen and Atwood 
2004). In other words, the Reproductive-Cell Cycle Theory of Aging proposes that the 
hormones that regulate reproduction, promote growth and development early in life but in 
later life become dysregulated and drive senescence (Bowen and Atwood 2004).  
Loss of testosterone is associated with loss of muscle mass and strength and decreased bone 
mineral density, thus increasing the risk of functional limitation, disability, fracture and falls 
(Lang, et al. 2010). Menopause is associated with loss of bone mass and also muscle strength 
(M.S. John Pathy 2006). GH stimulates growth during early life and is required for 
maintenance of muscle and bone in adulthood. GH exerts most of its action through insulin 
like growth factor (IGF-I). These are critical hormones in maintaining muscle and bone mass 
(Borst 2004). Without adequate levels it is impossible for anyone to maintain lean body mass, 
regardless of how well they eat or exercise. Secretion of GH is impaired in older people.  
A recent review by Borst SE suggested that testosterone replacement in elderly hypogonadal 
men produces only modest increases in muscle mass and strength, which are observed in 
some and not all studies (Borst 2004). Furthermore, higher doses have not been given for fear 
of accelerating prostate cancer. With regards to GH, this review shows that growth hormone 
replacement in older people produces a high incidence of side effects, does not increase 
strength and does not augment strength gains resulting from resistance training (Borst 2004).  
A review on hormone (testosterone or growth hormone) replacement to the older people 
produces only modest increases in muscle mass and strength in some but not all studies and 
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the risks associated with hormone replacements are still not clear (Borst 2004). To date, 
exercise and more importantly resistance training remains the most effective intervention 
for increasing muscle mass and strength in older people. 
6. A diagnostic approach to sarcopenia 
The EWGSOP proposed a practical approach to screen for sarcopenia in clinical practice 
(Cruz-Jentoft, et al. 2010a). This is as shown in Figure 4. This algorithm is based on gait 
speed measurement with a cut-off point of > 0.8 m/s.  
7. Conclusion 
Loss of muscle mass and strength with age is a slow but progressive process with 
undesirable consequences. The research in sarcopenia has shown that sarcopenia is linked to 
multiple causations: the aging process itself, genetic susceptibility, lifestyle practices, 
changes in living conditions and numerous chronic diseases. Sarcopenia also represents a 
set of unfavourable outcomes, such as the primary outcomes of loss of muscle mass, 
strength and quality, and secondary outcomes which cause further functional limitation, 
loss of mobility and increased risk of disability, falls and fractures. Current research has 
shown promising results on the assessment of sarcopenia and practical approach to the 
management of sarcopenic patients and/or patients at risk of sarcopenia in terms of 
prevention as well as its treatment. Sarcopenia is firmly on the agenda for research into 
ageing and needs to be recognised in routine clinical practice. 
 
Source: Report of the EWGSOP. Sarcopenia: European consensus on definition and diagnosis. Age and 
Ageing, 2010: 39: 412-423. 
Fig. 4. EWGSOP suggested algorithm for screening and case finding of sarcopenia 
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